JP2019533691A - 心血管疾患の予防及び／又は治療のための組成物 - Google Patents

心血管疾患の予防及び／又は治療のための組成物 Download PDF

Info

Publication number
JP2019533691A
JP2019533691A JP2019522777A JP2019522777A JP2019533691A JP 2019533691 A JP2019533691 A JP 2019533691A JP 2019522777 A JP2019522777 A JP 2019522777A JP 2019522777 A JP2019522777 A JP 2019522777A JP 2019533691 A JP2019533691 A JP 2019533691A
Authority
JP
Japan
Prior art keywords
extract
composition
use according
disease
thylakoid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
JP2019522777A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019533691A5 (https=
Inventor
アンドレ・ペー・ブレ
テオフィルス・ジェイ・ガナ
ナタリー・ブーシェ
Original Assignee
グループ・サンテ・デヴォニアン・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グループ・サンテ・デヴォニアン・インコーポレイテッド filed Critical グループ・サンテ・デヴォニアン・インコーポレイテッド
Publication of JP2019533691A publication Critical patent/JP2019533691A/ja
Publication of JP2019533691A5 publication Critical patent/JP2019533691A5/ja
Revoked legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/065—Diphenyl-substituted acyclic alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Medicines Containing Plant Substances (AREA)
JP2019522777A 2016-11-04 2017-11-03 心血管疾患の予防及び／又は治療のための組成物 Revoked JP2019533691A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662417415P 2016-11-04 2016-11-04
US62/417,415 2016-11-04
PCT/CA2017/051306 WO2018081903A1 (en) 2016-11-04 2017-11-03 Composition for the prevention and/or treatment of cardiovascular diseases

Publications (2)

Publication Number Publication Date
JP2019533691A true JP2019533691A (ja) 2019-11-21
JP2019533691A5 JP2019533691A5 (https=) 2020-12-17

Family

ID=62076517

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019522777A Revoked JP2019533691A (ja) 2016-11-04 2017-11-03 心血管疾患の予防及び／又は治療のための組成物

Country Status (5)

Country Link
US (1) US11033592B2 (https=)
EP (1) EP3534924A4 (https=)
JP (1) JP2019533691A (https=)
CA (1) CA3039681A1 (https=)
WO (1) WO2018081903A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230056443A1 (en) * 2021-08-21 2023-02-23 Nathalie Boucher Equine gastric health formulation
CN115786246B (zh) * 2022-12-16 2024-09-06 四川轻化工大学 斑马鱼免疫无应答性心力衰竭模型的构建方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003519191A (ja) * 1999-12-30 2003-06-17 ピュアセル・テクノロジーズ・インコーポレーテッド 光合成生物からチラコイドを得る方法、その方法から得られる植物画分、純粋チラコイド、およびｒｏｓスカベンジャー、光保護剤、バイオセンサー、バイオフィルターおよびバイオリアクターとしてチラコイドを使用する方法
JP2004535458A (ja) * 2001-07-02 2004-11-25 ピュアセル・テクノロジーズ・インコーポレーテッド 炎症過程の調節に有用なチラコイドを含む組成物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005027944A1 (en) 2003-09-22 2005-03-31 Purecell Technologies Inc. Oral compositions and route of administration for the delivery of a thylakoid extract
EP2320919B1 (en) * 2008-07-14 2016-03-30 Thylabisco Ab Large-scale process for the preparation of thylakoids

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003519191A (ja) * 1999-12-30 2003-06-17 ピュアセル・テクノロジーズ・インコーポレーテッド 光合成生物からチラコイドを得る方法、その方法から得られる植物画分、純粋チラコイド、およびｒｏｓスカベンジャー、光保護剤、バイオセンサー、バイオフィルターおよびバイオリアクターとしてチラコイドを使用する方法
JP2004535458A (ja) * 2001-07-02 2004-11-25 ピュアセル・テクノロジーズ・インコーポレーテッド 炎症過程の調節に有用なチラコイドを含む組成物

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BIOMEDICINES, 2020, VOL.8, #219, JPN6021038169, ISSN: 0004638407 *
J. SCI. FOOD AGRIC., 2015.9, VOL.96, PP.2337-2343, JPN6021038171, ISSN: 0004638409 *
NUTRITION AND CANCER, 2003, VOL.46, NO.2, PP.222-231, JPN6021038170, ISSN: 0004638408 *
PHYTOTHER. RES., 2009, VOL.23, PP.1778-1783, JPN6021038172, ISSN: 0004638410 *
PRELIMINARY PROSPECTUS, ORLETTO CAPITAL INC, 2016.8, [RETREIEVED ON 2021_09_22], JPN6021038167, ISSN: 0004797049 *

Also Published As

Publication number Publication date
EP3534924A4 (en) 2020-07-01
US20190314433A1 (en) 2019-10-17
CA3039681A1 (en) 2018-05-11
US11033592B2 (en) 2021-06-15
WO2018081903A1 (en) 2018-05-11
EP3534924A1 (en) 2019-09-11

Similar Documents

Publication Publication Date Title
Agbor et al. Antioxidant and anti-atherogenic activities of three Piper species on atherogenic diet fed hamsters
Cherubini et al. Role of anti-oxidants in atherosclerosis: epidemiological and clinical update
US20220313645A1 (en) Methods of treating hypertriglyceridemia
KR101383006B1 (ko) 고중성지방혈증 치료 방법
US10888539B2 (en) Methods of treating or preventing prostate cancer
Choi et al. Positive effects of astaxanthin on lipid profiles and oxidative stress in overweight subjects
Jankowski et al. Coenzyme Q10–A new player in the treatment of heart failure?
US20200061011A1 (en) Methods of treating hypercholesterolemia
US10525087B2 (en) Flowable concentrated phospholipid krill oil composition
de Moraes Arnoso et al. Açaí seed extract (ASE) rich in proanthocyanidins improves cardiovascular remodeling by increasing antioxidant response in obese high-fat diet-fed mice
Yang et al. Effect of astaxanthin on metabolic cataract in rats with type 1 diabetes mellitus
KR20150089009A (ko) 항산화 식이 보충제
Kottakis et al. Effects of mastic gum Pistacia lentiscus var. Chia on innate cellular immune effectors
JP2009298810A (ja) 炎症過程の調節に有用なチラコイドを含む組成物
JP2019533691A (ja) 心血管疾患の予防及び／又は治療のための組成物
CN109661238A (zh) 治疗红细胞疾病的治疗组合
Morihara et al. Aged garlic extract inhibits homocysteine-induced scavenger receptor CD36 expression and oxidized low-density lipoprotein cholesterol uptake in human macrophages in vitro
Taylor et al. Effects of intravenous administration of ascorbic acid (vitamin C) on oxidative status in healthy adult horses
Chen et al. Extract of Zanthoxylum bungeanum Maxim Seed Oil Reduces Hyperlipidemia in Hamsters Fed High-Fat Diet via Activation of Peroxisome Proliferator-Activated Receptor y.
US20030229124A1 (en) Lipid peroxide-lowering compositions
Whitehouse et al. NSAID gastropathy: prevention by celery seed extracts in disease-stressed rats
Orekhov Anti-atherosclerotic drugs from natural products
JP2018536701A (ja) 炎症性腸疾患の治療用のチラコイド抽出組成物及び製剤
Muid et al. Tocotrienol rich fraction supplement reduces oxidative stress in non familial hypercholesterolaemia: beyond the lipid lowering capability.
Hugo Jesús Antioxidant Capacity and Protective Effect of Aqueous and Hydroalcoholic Extracts of Senecio rhizomatus Rusby" Llancahuasi" on Erythrocytes Subjected to Oxidative Stress

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190627

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201102

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201102

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211004

AA91 Notification that invitation to amend document was cancelled

Free format text: JAPANESE INTERMEDIATE CODE: A971091

Effective date: 20211102

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211115

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220613